FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2976997434> ?p ?o ?g. }

• W2976997434 endingPage "536" @default.
• W2976997434 startingPage "532" @default.
• W2976997434 abstract "Abstract Tagraxofusp-erzs (Elzonris, Stemline) is a cytotoxin that targets CD123-expressing cells. On December 21, 2018, FDA approved tagraxofusp-erzs for the treatment of blastic plasmacytoid dendritic cell neoplasms (BPDCN) in adult and pediatric patients 2 years and older. Approval was based on the response rate in a single-arm trial, Study STML-401-0114; the pivotal cohort included 13 patients with treatment-naïve BPDCN who received tagraxofusp-erzs monotherapy. The complete response or clinical complete response (CR/CRc) rate in the pivotal cohort was 54% (95% CI: 25%–81%), and the median duration of CR/CRc was not reached with a median follow-up of 11.5 months (range: 0.2–12.7). In a separate exploratory cohort, a CR/CRc was achieved by 2 (13%) patients with R/R BPDCN. Safety was assessed in 94 patients with myeloid neoplasms treated with tagraxofusp-erzs at the approved dose and schedule. The major toxicity was capillary leak syndrome (CLS), which occurred in 55% of patients and was fatal in 2%. Hepatotoxicity and hypersensitivity reactions were reported in 88% and 46% of patients, respectively. Other common (≥30%) adverse reactions were nausea, fatigue, peripheral edema, pyrexia, and weight increase. A high proportion of patients (85%) developed neutralizing antidrug antibodies. Tagraxofusp-erzs is the first FDA-approved treatment for BPDCN." @default.
• W2976997434 created "2019-10-03" @default.
• W2976997434 creator A5004483141 @default.
• W2976997434 creator A5009227178 @default.
• W2976997434 creator A5013196129 @default.
• W2976997434 creator A5026362268 @default.
• W2976997434 creator A5028296024 @default.
• W2976997434 creator A5029612220 @default.
• W2976997434 creator A5041458996 @default.
• W2976997434 creator A5046390137 @default.
• W2976997434 creator A5051520990 @default.
• W2976997434 creator A5064564309 @default.
• W2976997434 creator A5066528744 @default.
• W2976997434 creator A5074097054 @default.
• W2976997434 creator A5076377082 @default.
• W2976997434 creator A5078022350 @default.
• W2976997434 creator A5080034477 @default.
• W2976997434 creator A5080059584 @default.
• W2976997434 creator A5089125177 @default.
• W2976997434 date "2020-02-01" @default.
• W2976997434 modified "2023-10-14" @default.
• W2976997434 title "FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm" @default.
• W2976997434 cites W134975557 @default.
• W2976997434 cites W2097881820 @default.
• W2976997434 cites W2107398329 @default.
• W2976997434 cites W2147937183 @default.
• W2976997434 cites W2156430381 @default.
• W2976997434 cites W2528978902 @default.
• W2976997434 cites W2756267360 @default.
• W2976997434 cites W2888511806 @default.
• W2976997434 cites W2955983368 @default.
• W2976997434 doi "https://doi.org/10.1158/1078-0432.ccr-19-2329" @default.
• W2976997434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31548341" @default.
• W2976997434 hasPublicationYear "2020" @default.
• W2976997434 type Work @default.
• W2976997434 sameAs 2976997434 @default.
• W2976997434 citedByCount "54" @default.
• W2976997434 countsByYear W29769974342019 @default.
• W2976997434 countsByYear W29769974342020 @default.
• W2976997434 countsByYear W29769974342021 @default.
• W2976997434 countsByYear W29769974342022 @default.
• W2976997434 countsByYear W29769974342023 @default.
• W2976997434 crossrefType "journal-article" @default.
• W2976997434 hasAuthorship W2976997434A5004483141 @default.
• W2976997434 hasAuthorship W2976997434A5009227178 @default.
• W2976997434 hasAuthorship W2976997434A5013196129 @default.
• W2976997434 hasAuthorship W2976997434A5026362268 @default.
• W2976997434 hasAuthorship W2976997434A5028296024 @default.
• W2976997434 hasAuthorship W2976997434A5029612220 @default.
• W2976997434 hasAuthorship W2976997434A5041458996 @default.
• W2976997434 hasAuthorship W2976997434A5046390137 @default.
• W2976997434 hasAuthorship W2976997434A5051520990 @default.
• W2976997434 hasAuthorship W2976997434A5064564309 @default.
• W2976997434 hasAuthorship W2976997434A5066528744 @default.
• W2976997434 hasAuthorship W2976997434A5074097054 @default.
• W2976997434 hasAuthorship W2976997434A5076377082 @default.
• W2976997434 hasAuthorship W2976997434A5078022350 @default.
• W2976997434 hasAuthorship W2976997434A5080034477 @default.
• W2976997434 hasAuthorship W2976997434A5080059584 @default.
• W2976997434 hasAuthorship W2976997434A5089125177 @default.
• W2976997434 hasBestOaLocation W29769974342 @default.
• W2976997434 hasConcept C126322002 @default.
• W2976997434 hasConcept C141071460 @default.
• W2976997434 hasConcept C197934379 @default.
• W2976997434 hasConcept C2777482430 @default.
• W2976997434 hasConcept C2779282312 @default.
• W2976997434 hasConcept C2780580376 @default.
• W2976997434 hasConcept C29730261 @default.
• W2976997434 hasConcept C71924100 @default.
• W2976997434 hasConcept C72563966 @default.
• W2976997434 hasConcept C90924648 @default.
• W2976997434 hasConceptScore W2976997434C126322002 @default.
• W2976997434 hasConceptScore W2976997434C141071460 @default.
• W2976997434 hasConceptScore W2976997434C197934379 @default.
• W2976997434 hasConceptScore W2976997434C2777482430 @default.
• W2976997434 hasConceptScore W2976997434C2779282312 @default.
• W2976997434 hasConceptScore W2976997434C2780580376 @default.
• W2976997434 hasConceptScore W2976997434C29730261 @default.
• W2976997434 hasConceptScore W2976997434C71924100 @default.
• W2976997434 hasConceptScore W2976997434C72563966 @default.
• W2976997434 hasConceptScore W2976997434C90924648 @default.
• W2976997434 hasIssue "3" @default.
• W2976997434 hasLocation W29769974341 @default.
• W2976997434 hasLocation W29769974342 @default.
• W2976997434 hasLocation W29769974343 @default.
• W2976997434 hasOpenAccess W2976997434 @default.
• W2976997434 hasPrimaryLocation W29769974341 @default.
• W2976997434 hasRelatedWork W2003938723 @default.
• W2976997434 hasRelatedWork W2047967234 @default.
• W2976997434 hasRelatedWork W2118496982 @default.
• W2976997434 hasRelatedWork W2364998975 @default.
• W2976997434 hasRelatedWork W2439875401 @default.
• W2976997434 hasRelatedWork W2603773853 @default.
• W2976997434 hasRelatedWork W3120865475 @default.
• W2976997434 hasRelatedWork W4238867864 @default.
• W2976997434 hasRelatedWork W4385476617 @default.
• W2976997434 hasRelatedWork W2525756941 @default.
• W2976997434 hasVolume "26" @default.

• next